<p><em>Lead program 是一個準備進入第一階段的 EBV 疫苗候選者，具有預防傳染性單核細胞增多症及與 EBV 感染相關的嚴重長期疾病的潛力</em></p>
<p>, /PRNewswire/ -- Vaccine Company, Inc.（Vaccine Company），一傢俬人持有的臨牀前生物技術公司，正在開發針對傳染病的下一代疫苗，今天宣佈已達成最終協議，將被禮來收購。</p>
<p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="400" height="101" original-src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg"/></p>
<p>Vaccine Company 的專有體內納米顆粒（IVN）技術旨在實現抗原展示，以引發與類病毒顆粒疫苗相關的持久免疫反應，同時避免傳統 VLP 生產的製造負擔。該公司正在推進一個涵蓋多種病毒病原體的廣泛臨牀前管線；其主導項目將該技術應用於 Epstein-Barr 病毒（EBV），並擁有一個五抗原的第一階段準備候選者。考慮到越來越多的證據將 EBV 與多發性硬化症和幾種惡性腫瘤聯繫在一起，預防性疫苗不僅可以預防急性傳染性單核細胞增多症，還可以防止感染後可能出現的長期神經和腫瘤後果。</p>
<p>根據協議條款，禮來將收購 Vaccine Company，Vaccine Company 的股東可能會獲得高達 15.5 億美元的現金，包括一次性付款和在達到特定臨牀和商業里程碑後支付的後續款項。</p>
<p>&#34;我們的項目管線，加上我們專有的體內納米顆粒（IVN）技術，具有全球影響的潛力，&#34; Vaccine Company 首席執行官 Susan Silbermann，MBA，MA 説，&#34;與禮來合作，我們將能夠推進我們的科學，推動項目開發，並最終向全球人民提供疫苗。&#34;</p>
<p>&#34;Epstein-Barr 病毒是世界上最普遍的人類病毒之一，但我們尚未擁有針對它的疫苗。Vaccine Company 建立了一個我們相信可能改變這一現狀的平台，&#34; 禮來首席科學官兼產品官、禮來研究實驗室總裁 Daniel M. Skovronsky，M.D.，Ph.D. 説。&#34;預防的理由遠不止於傳染性單核細胞增多症本身——現在的證據將 EBV 與多發性硬化症和幾種惡性腫瘤聯繫在一起，提前打斷這一鏈條可能會顯著減少這些疾病的長期負擔。&#34;</p>
<p>該交易需滿足慣常的成交條件，包括根據 1976 年 Hart-Scott-Rodino 反壟斷改進法案的等待期到期。</p>
<p>Lazard 擔任獨家財務顧問，Cooley LLP 擔任 Vaccine Company 的法律顧問。</p>
<p><strong>關於 Vaccine Company</strong></p>
<p>Vaccine Company 是一傢俬人持有的臨牀前生物技術公司，成立的目的是將下一代抗原工程引入疫苗科學。該公司的專有體內納米顆粒（IVN）技術旨在結合 mRNA 和類病毒顆粒方法的優勢，以實現對具有挑戰性的病毒靶標的持久、多價免疫反應。Vaccine Company 正在推進一系列臨牀前和 IND 啓動項目，主導項目是針對由 Epstein-Barr 病毒引起的傳染性單核細胞增多症的預防疫苗候選者。該公司於 2022 年由 ARCH Venture Partners 創立，Luma Group 作為共同創始投資者加入，此外還獲得了 Pfizer Ventures、Wellcome Trust、Lilly Ventures 和全球健康投資公司的進一步支持。</p>
<p><strong>聯繫信息</strong></p>
<p>Morgan Warners, FGS Global</p>
<p>Morgan.warners@fgsglobal.com</p>
<p><img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yNiZzbj1EQzY3NDA1?x-oss-process=image/auto-orient,1/interlace,1/resize,w_1440,h_1440/quality,q_95/format,jpg" alt="" width="16" height="16" original-src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yNiZzbj1EQzY3NDA1"/></p>
<p>查看原始內容以下載多媒體：https://www.prnewswire.com/news-releases/vaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html</p>
<p>來源 Vaccine Company</p>

禮來

動態生物技術與基因組 ETF - Invesco

紐交所高增長板生物技術指數 ETF - First Trust

<p>Vaccine Company, Inc. 已與禮來達成最終協議，將以高達 15.5 億美元的價格被收購。此次收購旨在推進一款針對埃比斯坦 - 巴爾病毒（EBV）的 1 期準備疫苗候選者，該疫苗有望預防傳染性單核細胞增多症及相關的長期健康問題。該交易需滿足慣常的成交條件，兩家公司均認為此次合作將增強疫苗開發和全球健康影響</p>

<p><em>Lead program is a Phase 1-ready EBV vaccine candidate with potential to prevent infectious mononucleosis and the serious long-term conditions associated with EBV infection</em></p>
<div class="lb-trans"><p><em>Lead program 是一個準備進入第一階段的 EBV 疫苗候選者，具有預防傳染性單核細胞增多症及與 EBV 感染相關的嚴重長期疾病的潛力</em></p>
</div><p>, /PRNewswire/ -- Vaccine Company, Inc. (Vaccine Company), a privately held pre-clinical-stage biotechnology company developing next-generation vaccines for infectious diseases, today announced entry into a definitive agreement to be acquired by Lilly.</p>
<div class="lb-trans"><p>, /PRNewswire/ -- Vaccine Company, Inc.（Vaccine Company），一傢俬人持有的臨牀前生物技術公司，正在開發針對傳染病的下一代疫苗，今天宣佈已達成最終協議，將被禮來收購。</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg" alt="" original-src="https://mma.prnewswire.com/media/2987379/Vaccine_Company_Logo.jpg"/></p>
<p>Vaccine Company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to enable the antigen display known to elicit durable immune responses associated with virus-like particle vaccines, while avoiding the manufacturing burden of traditional VLP production. The company is advancing a broad preclinical pipeline spanning multiple viral pathogens; the lead program applies this technology to Epstein-Barr Virus (EBV) with a five-antigen Phase 1-ready candidate. Given the growing evidence linking EBV to multiple sclerosis and several malignancies, a prophylactic vaccine could prevent not only acute infectious mononucleosis but also the long-term neurological and oncological consequences that may follow infection.</p>
<div class="lb-trans"><p>Vaccine Company 的專有體內納米顆粒（IVN）技術旨在實現抗原展示，以引發與類病毒顆粒疫苗相關的持久免疫反應，同時避免傳統 VLP 生產的製造負擔。該公司正在推進一個涵蓋多種病毒病原體的廣泛臨牀前管線；其主導項目將該技術應用於 Epstein-Barr 病毒（EBV），並擁有一個五抗原的第一階段準備候選者。考慮到越來越多的證據將 EBV 與多發性硬化症和幾種惡性腫瘤聯繫在一起，預防性疫苗不僅可以預防急性傳染性單核細胞增多症，還可以防止感染後可能出現的長期神經和腫瘤後果。</p>
</div><p>Under the terms of the agreement, Lilly will acquire Vaccine Company, and Vaccine Company equity holders could receive up to $1.55 billion in cash, inclusive of an upfront payment and subsequent payments payable upon the achievement of specified clinical and commercial milestones.</p>
<div class="lb-trans"><p>根據協議條款，禮來將收購 Vaccine Company，Vaccine Company 的股東可能會獲得高達 15.5 億美元的現金，包括一次性付款和在達到特定臨牀和商業里程碑後支付的後續款項。</p>
</div><p>&#34;Our pipeline of programs, coupled with our proprietary In Vivo Nanoparticle (IVN) technologies, have the potential for global impact,&#34; said Susan Silbermann, MBA, MA, Chief Executive Officer of Vaccine Company, &#34;Together with Lilly, we will be positioned to advance our science, move programs through development, and ultimately deliver vaccines to people around the world.&#34;</p>
<div class="lb-trans"><p>&#34;我們的項目管線，加上我們專有的體內納米顆粒（IVN）技術，具有全球影響的潛力，&#34; Vaccine Company 首席執行官 Susan Silbermann，MBA，MA 説，&#34;與禮來合作，我們將能夠推進我們的科學，推動項目開發，並最終向全球人民提供疫苗。&#34;</p>
</div><p>&#34;Epstein-Barr virus is among the most prevalent human viruses in the world, yet we do not yet have a vaccine against it. Vaccine Company has built a platform we believe may be capable of changing that,&#34; said Daniel M. Skovronsky, M.D., Ph.D., Lilly's chief scientific and product officer, and president, Lilly Research Laboratories. &#34;The case for prevention extends well beyond infectious mononucleosis itself — evidence now links EBV to multiple sclerosis and several malignancies and interrupting that chain earlier could meaningfully reduce the long-term burden of these diseases.&#34;</p>
<div class="lb-trans"><p>&#34;Epstein-Barr 病毒是世界上最普遍的人類病毒之一，但我們尚未擁有針對它的疫苗。Vaccine Company 建立了一個我們相信可能改變這一現狀的平台，&#34; 禮來首席科學官兼產品官、禮來研究實驗室總裁 Daniel M. Skovronsky，M.D.，Ph.D. 説。&#34;預防的理由遠不止於傳染性單核細胞增多症本身——現在的證據將 EBV 與多發性硬化症和幾種惡性腫瘤聯繫在一起，提前打斷這一鏈條可能會顯著減少這些疾病的長期負擔。&#34;</p>
</div><p>The transaction is subject to customary closing conditions, including expiration of the waiting period under the Hart-Scott-Rodino Antitrust Improvements Act of 1976.</p>
<div class="lb-trans"><p>該交易需滿足慣常的成交條件，包括根據 1976 年 Hart-Scott-Rodino 反壟斷改進法案的等待期到期。</p>
</div><p>Lazard is acting as exclusive financial advisor, and Cooley LLP is acting as legal counsel to Vaccine Company.</p>
<div class="lb-trans"><p>Lazard 擔任獨家財務顧問，Cooley LLP 擔任 Vaccine Company 的法律顧問。</p>
</div><p><strong>About Vaccine Company</strong></p>
<div class="lb-trans"><p><strong>關於 Vaccine Company</strong></p>
</div><p>Vaccine Company is a privately held pre-clinical-stage biotechnology company founded to bring next-generation antigen engineering to vaccine science. The company's proprietary In Vivo Nanoparticle (IVN) technologies are designed to combine the strengths of mRNA and virus-like particle approaches to enable durable, multivalent immune responses to challenging viral targets. Vaccine Company is advancing a pipeline of preclinical and IND-enabling programs, led by a vaccine candidate for the prevention of infectious mononucleosis caused by Epstein-Barr virus. The company was founded in 2022 by ARCH Venture Partners. Luma Group joined as co-founding investor, with further backing from Pfizer Ventures, Wellcome Trust, Lilly Ventures, and Global Health Investment Corporation.</p>
<div class="lb-trans"><p>Vaccine Company 是一傢俬人持有的臨牀前生物技術公司，成立的目的是將下一代抗原工程引入疫苗科學。該公司的專有體內納米顆粒（IVN）技術旨在結合 mRNA 和類病毒顆粒方法的優勢，以實現對具有挑戰性的病毒靶標的持久、多價免疫反應。Vaccine Company 正在推進一系列臨牀前和 IND 啓動項目，主導項目是針對由 Epstein-Barr 病毒引起的傳染性單核細胞增多症的預防疫苗候選者。該公司於 2022 年由 ARCH Venture Partners 創立，Luma Group 作為共同創始投資者加入，此外還獲得了 Pfizer Ventures、Wellcome Trust、Lilly Ventures 和全球健康投資公司的進一步支持。</p>
</div><p><strong>Contact Information</strong></p>
<div class="lb-trans"><p><strong>聯繫信息</strong></p>
</div><p>Morgan Warners, FGS Global</p>
<div class="lb-trans"><p>Morgan Warners, FGS Global</p>
</div><p>Morgan.warners@fgsglobal.com</p>
<div class="lb-trans"><p>Morgan.warners@fgsglobal.com</p>
</div><p><img src="https://imageproxy.pbkrs.com/https://edge.prnewswire.com/c/img/favicon.png/query-c2Q9MjAyNi0wNS0yNiZzbj1EQzY3NDA1" alt="" original-src="https://edge.prnewswire.com/c/img/favicon.png?sn=DC67405&amp;sd=2026-05-26"/></p>
<p>View original content to download multimedia:https://www.prnewswire.com/news-releases/vaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html</p>
<div class="lb-trans"><p>查看原始內容以下載多媒體：https://www.prnewswire.com/news-releases/vaccine-company-to-be-acquired-by-lilly-to-advance-best-in-class-vaccine-candidates-for-epstein-barr-virus-and-other-infectious-diseases-302781387.html</p>
</div><p>SOURCE Vaccine Company</p>
<div class="lb-trans"><p>來源 Vaccine Company</p>
</div>

Vaccine Company to be acquired by Lilly to advance best-in-class vaccine candidates for Epstein-Barr Virus and other infectious diseases

Fidelity

納斯達克生物科技指數 ETF - iShares Nasdaq

基因改革 ETF - ARK

醫藥突破 ETF - ALPS

2 倍做多納斯達克生物技術 ETF - ProShares

醫療業 ETF - Vanguard

美國制藥 ETF - iShares

2 倍做多 LLY ETF - Defiance

生物科技 ETF - VanEck Vectors

2 倍做多 LLY ETF - Direxion

標普生物技術 ETF - SPDR

標普生物技術 3 倍做多 - Direxion

Invesco Nasdaq Biotechnology ETF

醫療業 ETF - SPDR

Lazard

輝瑞

疫苗公司將被禮來收購，以推進針對 Epstein-Barr 病毒及其他傳染病的頂級疫苗候選產品